Data Sheet (Cat.No.T11825)

TargetMol

LCB-2853

Chemical Properties



CAS No. : 141335-10-6

Formula: C21H24ClNO4S

Molecular Weight: 421.94

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	LCB-2853 is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects.
Targets(IC50)	PPAR,Prostaglandin Receptor
In vivo	In dog coronary stenosis, LCB 2853 demonstrates high efficacy with an ED50 of 7.2 μg/kg. In rat venous thrombosis induced by venous injury and blood stasis, perfused LCB 2853 reduces thrombus weight in a dose-dependent manner with an ED50 of 220 μg/kg/min[1]. In vivo, LCB 2853 shows an ED50 below 1 mg/kg i.v. against platelet aggregation and vasoconstriction, observed in rat arachidonic acid (AA)-induced thrombocytopenia or U 46619-induced hypertension (ED50 = 0.25 and 0.16 mg/kg) and in AA-induced sudden death in mice (ED50 = 0.44 mg/kg). Additionally, LCB 2853 effectively blocks U 46619-induced bronchoconstriction after i.v. administration (ED50 = 18.4 μg/kg)[2].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.370 mL	11.850 mL	23.7001 mL
5 mM	0.474 mL	2.370 mL	4.740 mL
10 mM	0.237 mL	1.185 mL	2.370 mL
50 mM	0.0474 mL	0.237 mL	0.474 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Lardy C, et al. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Arzneimittelforschung. 1994 Nov;44(11):1196-202.

Depin JC, et al. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl] benzeneacetate. Arzneimittelforschung. 1994 Nov;44(11):1203-7.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481